SAN DIEGO, May 22, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) announced today that portfolio company KannalifeSciences, Inc. ("Kannalife"), a bio-pharmaceutical and phyto-medical company, was featured in a Dateline NBC segment discussing how their research on cannabidiol (CBD)-like molecules could potentially change the landscape for various ailments including
The May 20, 2018, segment entitled "Growing Promise" took an in-depth look into Kannalife Sciences and their groundbreaking research investigating whether the Company's proprietary CBD-like molecules can help change the medical landscape and offer several new treatments for specific ailments.
"We are honored to be featured in this Dateline NBC special and thankful to be able to educate people on the therapeutic benefits of cannabinoids and how companies like Kannalife are working to conduct the necessary research on cannabinoid-like molecules to bring new drugs to market," said Kannalife Sciences CEO Dean Petkanas. "We are excited to have such great exposure and look forward to sharing many more updates on our research in the future."
A significant portion of this segment focused on the problem of CTE, a degenerative neurological disease caused by repeated head trauma that can lead to symptoms like violent mood swings, depression and other cognitive difficulties. Currently, CTE can only be definitively diagnosed by direct tissue examination after death. Because there is not much known about this debilitating disease, treatment and prevention options are bleak.
Kannalife currently holds two licenses, one of them exclusive, with the National Institutes of Health (NIH) for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants," to research Hepatic Encephalopathy (HE) and CTE.
About Kannalife Sciences
Kannalife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants." Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat HE and CTE. HE and CTE are oxidative stress-related diseases that affect the cognitive and behavioral functions, and the wellness of the brain.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s video statement, click here.
Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
LEGAL DISCLOSUREMedical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
CONTACT:Public Relations Contact:Andrew HardChief Executive Officer CMW MediaP. 858-264-6600 firstname.lastname@example.org www.cmwmedia.com
View original content:http://www.prnewswire.com/news-releases/dateline-nbc-segment-features-medical-marijuana-inc-portfolio-company-kannalife-sciences-300652428.html
SOURCE Medical Marijuana, Inc.
Subscribe to our Free Newsletters!
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ...
Patisiran injection, recently approved by FDA to treat polyneuropathy, a disease that causes ...
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...View All